NGNE
Neurogene Inc
NASDAQ: NGNE · HEALTHCARE · BIOTECHNOLOGY
$26.48
-3.53% today
Updated 2026-04-29
Market cap
$422.41M
P/E ratio
—
P/S ratio
438.73x
EPS (TTM)
$-4.24
Dividend yield
—
52W range
$12 – $37
Volume
0.2M
Neurogene Inc (NGNE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-9.80M | $-7.23M | $-7.94M | $-17.81M | $-20.27M | $-30.23M | $-44.72M | $-31.58M | $-15.39M | $-24.57M | $-46.40M | $-52.82M | $-51.42M | $-70.60M | $-77.17M |
| Capital expenditures | $62849.00 | $6448.00 | $11746.00 | $113894.00 | $26999.00 | $713000.00 | $494000.00 | $49000.00 | $879000.00 | $2.22M | $18.37M | $2.23M | $321000.00 | $808000.00 | $1.18M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | — | — | — | — | — | — | — | $896000.00 | $1.25M | $1.42M | $8.32M | $14.18M |
| Free cash flow | $-9.86M | $-7.24M | $-7.95M | $-17.92M | $-20.29M | $-30.94M | $-45.21M | $-31.63M | $-16.27M | $-26.79M | $-64.77M | $-55.05M | $-51.74M | $-71.41M | $-78.36M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |